Clinical Trial Update: A Multicenter, Double Blinded, Randomized, Parallel Assignment Study to Demonstrate the Efficacy of DA9601 [Phase 4]

View source ↗

Summary

A multicenter, double-blind, randomized Phase 4 trial evaluating DA9601 for NSAID-induced gastroduodenal injury has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nsaid-induced Gastroduodenal Injury

Drugs mentioned

• DA9601

Snippet

Sponsor: Dong-A ST Co., Ltd. | Conditions: NSAID-associated Gastroduodenal Injury | Phase 4 | Status: COMPLETED